The Lipopolysaccharide binding protein (LBP, LPS-binding protein) ELISA is an enzyme immunoassay for the quantitative determination of Lipopolysaccharide binding protein (LBP, LPS-binding protein) in human serum and plasma.
The microtiter plate is coated with the antibody specifically binding the Lipopolysaccharide binding protein. The human serum or plasma is incubated in the plate with the capture antibody. The specimen is washed out and the specifically bound protein is incubated with biotin-labelled detection antibody. Following another washing step, Streptavidin-HRP conjugate is added into the well. Unbound reagent is then washed out. Horseradish peroxidase (HRP) bound in the complex reacts with the chromogenic substrate (TMB) creating the blue colour. The reaction is stopped by addition of STOP solution (H2SO4). The absorbance values are measured at 450 nm (optionally 450/630 nm) and are proportional to the concentration of LBP in the specimen. The concentration of LBP in unknown samples is determined from the calibration curve which is created by plotting the absorbance values against the standard concentration values.
Catalog No:BA3006
Regular price
$560.00 USD
Regular price
$560.00 USD
Sale price
$560.00 USD
Unit price/ per
Sale
Sold out
2 weeks
Couldn't load pickup availability
Product Details
Species ReactivityHuman
Sensitivity0.25 ng/mL
Detection Range1 - 32 ng/mL
Sample TypeSerum, Plasma
Sample Size5 uL
Incubation(s)2.5 hour(s)
Research AreasInfection immunity
BackgroundLipopolysaccharide binding protein (LBP, LPS-binding protein) is a serum glycoprotein belonging to the family of lipid-binding proteins. LBP is synthesized by hepatocytes and intestinal epithelial cells. Serum concentrations of LBP range between 5 and 10 ug/ml during homeostasis, increasing up to 200 ug/ml during the acute-phase response in the course of infection.
LBP expression and function are strongly associated with recognition and control of bacterial infection. LBP is an acute-phase reactant. As a class I acute-phase protein, LBP is induced by pro-inflammatory cytokines such as interleukins 1 and 6, tumor necrosis factor-alpha (TNF-alpha), and glucocorticoid hormones in liver and in non-hepatic tissues such as the gut and the lung.
LPS is released from CD14 in the lipid bilayer and binds to a complex of receptors including Toll-like receptor 4 (TLR-4) to initiate intracellular signaling cascades and transcription of genes mediated through NF-kB.
If dysregulated, these host reactions can have inadvertent outcomes such as severe sepsis, septic shock, or systemic inflammatory response syndrome (SIRS).
LBP binds LPS in various pathologic states including obesity and insulin resistance.
